



January 26, 2022

## **Spring Discovery Secures Exclusive License to Intellectual Property from Boston Children's Hospital**

*SAN CARLOS, California, 1/26/22* – Spring Discovery, Inc. announced today that the company has secured an exclusive license from Boston Children’s Hospital to fundamental intellectual property related to small molecule inhibitors of gasdermin pore formation and pyroptosis, a highly inflammatory programmed cell death process related to inflammasomes. This intellectual property was developed in part by Judy Lieberman, MD, Ph.D. and Hao Wu, Ph.D., Chair and Senior Investigator, respectively, of Cellular and Molecular Medicine at Boston Children’s Hospital. Under the terms of the license agreement, Boston Children’s Hospital will be eligible to receive milestone and royalty payments on the sale of any future therapeutic products that make use of the intellectual property licensed by Spring Discovery. Other terms of the agreement were not disclosed.

“We are excited to add this license from Boston Children’s Hospital to the growing portfolio of therapeutics- and platform-related intellectual property being developed and licensed at Spring Discovery,” said Ben Kamens, CEO and Founder of Spring Discovery. “We are discovering and developing novel therapeutics strategies for combating runaway inflammatory processes in many diseases that are common as we age. This license is an important component in our patent strategy for modulating inflammasome activation to treat multiple diseases.”

### **About Spring Discovery**

Spring Discovery builds world-leading technology to help scientists discover and develop therapies for age-related diseases. The company’s proprietary machine learning and wetlab automation platform is capable of generating high-dimensional phenotypic data that combines multiple modalities of biological readouts into single assays at unprecedented scale. This technology powers high-throughput therapeutic screens capable of measuring multiple cell behaviors while searching for therapies for multiple diseases associated with aging.

Spring Discovery's leaders and advisors are experts in machine learning, therapeutic discovery, and clinical development. The company's platform is being used for multiple programs in a wide range of diseases across both internal programs and partnerships.

**Contact:**

Spring Discovery, Inc  
press@springdiscovery.com